Related Experiment Video
Updated: Feb 15, 2026

Ubiquitous and Tissue-specific RNA Targeting in Drosophila Melanogaster using CRISPR/CasRx
Published on: February 5, 2021
Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target
Lisa Maria Mustachio1, Yun Lu2, Masanori Kawakami1
1Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Abstract:
Ubiquitination and ubiquitin-like posttranslational modifications (PTM) regulate activity and stability of oncoproteins and tumor suppressors. This implicates PTMs as antineoplastic targets. One way to alter PTMs is to inhibit activity of deubiquitinases (DUB) that remove ubiquitin or ubiquitin-like proteins from substrate proteins. Roles of DUBs in carcinogenesis have been intensively studied, yet few inhibitors exist. Prior work provides a basis for the ubiquitin-specific protease 18 (USP18) as an antineoplastic target. USP18 is the major DUB that removes IFN-stimulated gene 15 (ISG15) from conjugated proteins. Prior work discovered that engineered loss of USP18 increases ISGylation and in contrast to its gain decreases cancer growth by destabilizing growth-regulatory proteins. Loss of USP18 reduced cancer cell growth by triggering apoptosis. Genetic loss of USP18 repressed cancer formation in engineered murine lung cancer models. The translational relevance of USP18 was confirmed by finding its expression was deregulated in malignant versus normal tissues. Notably, the recent elucidation of the USP18 crystal structure offers a framework for developing an inhibitor to this DUB. This review summarizes strong evidence for USP18 as a previously unrecognized pharmacologic target in oncology. Cancer Res; 78(3); 587-92. ©2018 AACR.
Insights
Targeting deubiquitinases (DUBs) offers new cancer treatments. Inhibiting USP18, a key DUB, destabilizes cancer-promoting proteins, leading to apoptosis and repressed tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Posttranslational modifications (PTMs) like ubiquitination regulate key cancer proteins.
- Deubiquitinases (DUBs) are critical enzymes in PTM regulation and are potential antineoplastic targets.
- Few DUB inhibitors currently exist, highlighting a gap in cancer therapeutics.
Purpose of the Study:
- To evaluate ubiquitin-specific protease 18 (USP18) as a novel pharmacologic target in oncology.
- To summarize evidence supporting USP18's role in cancer progression and its potential as a therapeutic target.
Main Methods:
- Review of existing literature on USP18 function in cancer.
- Analysis of USP18's role in regulating ISG15 conjugation and its impact on protein stability.
- Examination of genetic models and tissue expression data to assess USP18's translational relevance.
Main Results:
- Engineered loss of USP18 increases ISGylation and decreases cancer growth by destabilizing growth-regulatory proteins.
- USP18 loss triggers apoptosis and represses cancer formation in murine lung cancer models.
- USP18 expression is deregulated in malignant versus normal tissues, confirming its translational relevance.
Conclusions:
- USP18 is a significant DUB involved in cancer progression.
- USP18 inhibition represents a promising therapeutic strategy for cancer treatment.
- The elucidated USP18 crystal structure provides a basis for developing targeted inhibitors.
Related Concept Videos
The Evidence for Evolution
Specific Heat
For example, increasing the temperature of one gram of water by 1°C requires one calorie of heat energy and can be written as 1 cal/g-°C, or...
Density, Specific Weight, Specific Gravity and Compressibility of Fluid
Specific weight represents the weight per unit volume and is calculated by multiplying...
Cell Specific Gene Expression
Targeted Cancer Therapies
There are several types of targeted therapies against...
Sensitivity, Specificity, and Predicted Value
Sensitivity is the...

